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Medi-Cal data were available on an 11-year time span
(July 1985–December 1996). Only the first episode of
treatment for each patient was considered. Patients were
further excluded if they were pregnant, they were in long-
term facilities before and at the keydate, and if they lost
their Medi-Cal eligibility during the study period.
RESULTS: In this study 30,200 patients met the eligibility
criteria (mean age 60.8  19.4, 67.1% female). Among
patients, 20.8% started their therapy with a calcium-
channel-blocker, 18.7% with a diuretic, and 18.6% with
a beta-blocker. Before the end of the study period, 94.2%
of patients either discontinued or interrupted their anti-
hypertensive medications. Average cost in the post-period
(e.g., hospital, ambulatory care, and all other costs but
prescription and long-term care) was $7945 for discon-
tinuing versus $7525 for continuing patients (Wilcoxon-
rank-sums test, p  0.0354).
CONCLUSIONS: Patients who interrupt their anti-
hypertensive medications cause a higher healthcare ex-
penditure than continuous patients. Further analyses are
needed considering co-factors that may influence health-
care utilization.
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OBJECTIVE: To compare the effects of hydroxymethyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) with non-statins on compliance duration, health-
care utilization, and healthcare costs in an health mainte-
nance organization (HMO) population.
METHODS: A retrospective cohort study was performed
using claims data and survey data in continuously en-
rolled patients (n  810) with prescriptions for antihy-
perlipidemic medications from April 1993 to March
1995. Compliance duration was defined as the duration
of over 80% compliance with antihyperlipidemic medica-
tions, healthcare utilization measures as hospital admis-
sions due to cardiac diseases and outpatient visits, and
healthcare cost variables as total healthcare costs, net
costs, and drug cost. Each main outcome measure was
modeled (Tobit model for compliance duration, probit
model for healthcare utilization, and OLS model for
healthcare costs).
RESULTS: The statins significantly prolonged the com-
pliance duration (p  0.05). The factors significantly in-
fluencing on compliance duration were female gender,
baseline high compliance, chronic disease scores, number
of cholesterol-lowering drugs in the regimen, and diag-
nostic characteristics such as peripheral vascular diseases
(PVD), cardiac diseases (CVD), hypertension, and diabe-
tes. The statins significantly decreased adjusted hospital
admissions due to CVD in year 1 (p  0.05) especially in
those patients with PVD (p  0.01) and CVD (p  0.05).
There was no significant difference in total healthcare
costs in year 1 between patients on statins and those on
non-statins. However, in year 2 and pooled data (year 1
and year 2), the statins were significantly associated with
higher total healthcare costs (p  0.05, p-pooled  0.05)
and higher drug costs (p  0.0001, p-pooled  0.0001).
CONCLUSIONS: The statins improved patient’s compli-
ance of antihyperlipidemic therapy. The statins also de-
creased the hospital admissions due to CVD without signif-
icantly elevated healthcare costs in the short term (year 1).
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The ultimate goal of pharmaceutical care is to improve
patient HRQoL. Although researchers have attempted
successfully to link pharmaceutical care behaviors with
HRQoL, the findings are not consistent. Furthermore,
the role of patient satisfaction and compliance in this re-
lationship needs to be explored.
OBJECTIVE: To test a path analytic model depicting the
association of pharmacists’ directive guidance behaviors,
patient satisfaction, compliance, and HRQoL. Pharma-
cists’ directive guidance behaviors were used as an indica-
tor of the level of pharmaceutical care.
METHODS: Five ambulatory care pharmacies/clinics
were selected for study participation. A 50-item question-
naire eliciting information about demographics, percep-
tion about pharmacists’ directive guidance behaviors, sat-
isfaction with pharmaceutical care behaviors, compliance
and HRQoL was administered to volunteers at each
study site. A total of 160 patients completed the ques-
tionnaire.
RESULTS: Bivariate correlations showed that directive
guidance behaviors were significantly correlated to pa-
tient satisfaction (r  0.56, p  0.001), and SF-12 Physi-
cal Component Summary (PCS) and Mental Component
Summary (MCS) scores (r  0.19, p  0.05; r 
0.19, p  0.05, respectively). Also, patient satisfaction
was significantly correlated to PCS (r  0.20, p 
0.05). Compliance was significantly correlated to PCS
(r  0.25, p  0.01) and MCS (r  0.23, p  0.01). Two
path analytic models using PCS and MCS as dependent
variables were tested. In path analysis with PCS as the de-
pendent variable, compliance had significant total causal
effect of 0.16 (p  0.05) that was due to its direct effect.
No other path coefficients were significant in this model.
In path analysis with MCS as the dependent variable, no
path coefficients were significant.
